Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis

Initiation of Basal Insulin Analog Treatment for Type 2 Diabetes and Reasons Behind Patients’ Treatment Persistence Behavior: Real-World Data from Germany

“…All of these factors were also identified in the current study. A German primary care database analysis additionally identified the type of insulin, type of oral antidiabetic comedication, and patient characteristics such as heart failure or higher age as factors associated with treatment persistence [16]. A similar German database study on patients from general and internal medicine practices study found the presence of depression and frequent or severe higher hypoglycemia to be predictors of early basal insulin discontinuation, while the use of insulin glargine rather than NPH insulin, and diabetologist rather than primary care were related with lower odds for early Article Thieme discontinuation [20].…”

“…A similar study found 2-year persistence rates of 65 %, 53 %, and 59 %, respectively, after initiation of insulin glargine, detemir, or NPH insulin, respectively [16]. Further research is therefore needed to help clinicians understand which factors drive patients' persistence behaviors and experiences after initiating insulin therapy.…”

“…Poor treatment adherence and persistence have been shown to affect the real-world effectiveness of insulin and negatively impacts desired clinical and economic outcomes [5][6][7][8][9][10][11][12][13]. While several studies have examined persistence with basal insulin treatment [8,10,[14][15][16][17][18][19][20][21], few studies have explored the patients' reasons for continuing treatment [19] or distinguished among patients who temporarily interrupted therapy versus those who discontinued insulin completely [14,18,19].…”

Clinical inertia to insulin initiation and intensification in the UK: A focused literature review

“…Reasons for stopping were unknown [18]. Pscherer et al [39] compared persistence after 2 years with treatment regimens involving insulin glargine, insulin detemir or neutral protamine Hagedorn insulin in combination with either a prandial insulin or an OAD. In basal-oral therapy regimens, 2-year persistence varied from 53% to 65%, whereas in intensified conventional therapy, persistence was around 85%.…”

Basal insulin initiation use and experience among people with type 2 diabetes mellitus with different patterns of persistence: results from a multi-national survey

“…Basal insulin options, currently including both intermediate-acting and long-acting formulations of insulin, are simpler and more convenient than mealtime or pre-mixed insulin 24,25 , ideally improving treatment persistence and/or adherence. However, while several studies have examined persistence with basal insulin treatment [15][16][17][18][26][27][28][29][30] , few studies have explored the patients' reasons for continuing treatment 29 or distinguished among patients who may temporarily interrupt therapy and those who discontinue 17,29 . Studies also have not described the patient experience during or after insulin initiation for patients with different persistence patterns.…”